Exogenous hyaluronidase induces release of nitric oxide from the coronary endothelium  by Evora, Paulo R.B. et al.
hyaluronidase infusion has been shown to reduce
ischemic injury due to coronary occlusion.1-4 In addi-
tion, myocardial preservation solutions containing
hyaluronidase have been shown to enhance functional
and metabolic recovery of treated hearts compared with
conventional preservation solutions.5
The exact mechanism of the protective action of
hyaluronidase is unknown. Although the enzymatic
action of hyaluronidase on cardiac hyaluronidate may
play a role, it is possible that hyaluronidase stimulates
the release of the endogenous vascular protectant, nitric
oxide. Nitric oxide prevents platelet adhesion6 and
aggregation,7 promotes platelet disaggregation in the
vasculature,7 and inhibits leukocyte adhesion8 and
aggregation9 and neutrophil superoxide anion produc-
tion.10,11 If hyaluronidase stimulates the endogenous
release of nitric oxide, this could be a mechanism of the
Hyaluronidase modifies the permeability of connec-tive tissue through the hydrolysis of hyaluronic
acid, a polysaccharide found in the intercellular ground
substance. In animal and in human studies,
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cardioprotective action of the compound. The purpose
of these experiments was to determine whether
hyaluronidase can induce the release of nitric oxide
from the coronary endothelium.
Materials and methods
Animal preparation. Heartworm-free mongrel dogs (25-
30 kg) of either sex were anesthetized with pentobarbital
sodium (30 mg/kg intravenous injection; Fort Dodge
Laboratories, Inc, Fort Dodge, Iowa) and exsanguinated.
Each dog’s chest was opened quickly, and the heart was har-
vested and immersed in cool, oxygenated physiologic salt
solution of the following composition (in millimoles per
liter): NaCl, 118.3; KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.22;
CaCl2, 2.5; NaHCO3, 25.0; calcium-ethylenediamine-
tetraacetic acid, 0.016; and glucose, 11.1 (control solution).
The procedures and handling of the animals were reviewed
and approved by the Institutional Animal Care and Use
Committee of the Mayo Foundation.
In vitro experiments. The left circumflex coronary artery
was carefully dissected free of connective tissue and placed in
the control solution. Segments (4-5 mm long) of blood vessel
were prepared; great care was taken not to touch the intimal sur-
face. In some segments, vascular smooth muscle function was
tested without the influence of the endothelium; in these rings,
the endothelium was removed by gently rubbing the intimal sur-
face of the blood vessel with a pair of watchmaker’s forceps.
This procedure removes endothelium but does not affect the
ability of vascular smooth muscle to contract or relax.12,13
Coronary artery segments, with and without endotheli-
um, were suspended in organ chambers (25 mL) filled with
control solution maintained at 37°C and aerated with 95%
oxygen and 5% carbon dioxide (pH = 7.4). Each ring was
suspended by 2 stainless steel clips passed through the
lumen. One clip was anchored to the bottom of the organ
chamber, and the other was connected to a strain gauge to
measure isometric force (Grass FTO3; Grass Instrument
Company, Quincy, Mass). The rings were placed at the
optimal point of their length-tension relationship by pro-
gressively stretching them until contraction to potassium
ions (20 mmol/L), at each level of distention, was maximal.
In all experiments, the presence or absence of endothelium
was confirmed by finding the response to acetylcholine
(10-6 mol/L) in rings contracted with potassium ions (20
mmol/L).12,13 After optimal tension was achieved, the arte-
rial segments were allowed to equilibrate for 30 to 45 min-
utes before administration of drugs.
Drugs. The following drugs were used: bovine testicular
hyaluronidase (150 USP units) (Wyeth Laboratories Inc,
Philadelphia, Pa); indomethacin (INN: indometacin),
prostaglandin F2α, methylene blue (Sigma Chemical Com-
pany, St Louis, Mo); and L-arginine, D-arginine, NG-
monomethyl-L-arginine (L-NMMA), and NG-nitro-L-arginine
(L-NOARG) (Calbiochem, San Diego, Calif). All powdered
drugs were prepared with distilled water except for
indomethacin, which was dissolved in Na2CO3 (10–5 mol/L).
Oxyhemoglobin was prepared by the method of Gillespie and
Sheng.14
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Fig 1.  Endothelium-dependent relaxation to hyaluronidase in canine coronary arteries (original traces). Blood ves-
sel segments with endothelium were contracted with prostaglandin F2α (PGF2 alpha; 2 × 10–6 mol/L) and exposed
to increasing amounts of hyaluronidase. Top trace, Control vasodilation; second trace, response to hyaluronidase
in the presence of NG-monomethyl-L-arginine (L-NMMA); third trace, vasodilation to hyaluronidase in the presence
of L-NMMA and L-arginine (L-Arg); bottom trace, response to hyaluronidase in the presence of L-NMMA and D-
arginine (D-Arg).
In some experiments, the enzymatic function of
hyaluronidase was inactivated by heat by boiling the com-
pound for 30 minutes. The sodium bicarbonate in the control
solution, in addition to aeration with 5% carbon dioxide, has
a buffering action in the organ bath that keeps the pH at 7.4.
Thus, the addition of hyaluronidase, L-NMMA, L-arginine, or
D-arginine did not alter organ bath pH. Unless otherwise stat-
ed, all drug concentrations are expressed as final molar con-
centration in the organ chambers. The effect of hyaluronidase
on vascular reactivity of arterial segments with and without
endothelium was studied on untreated arteries (control) or on
arterial segments that were treated with L-NMMA (10–5
mol/L), L-NMMA plus L-arginine (10–4 mol/L), L-NMMA
plus D-arginine (10–4 mol/L), L-NOARG (10–5 mol/L), hemo-
globin (2 × 10–6 mol/L), and methylene blue (10–5 mol/L). All
blockers were added to the organ bath at least 15 minutes
before the coronary artery contractions with prostaglandin
F2α (2 × 10–6 mol/L). All experiments were performed in the
presence of indomethacin (10–6 mol/L) to prevent the synthe-
sis of endogenous prostanoids.
Data analysis. Results are expressed as mean ± standard
error of the mean. In all experiments, “n” refers to the num-
ber of animals from which blood vessels were taken. In seg-
ments contracted with prostaglandin F2α, responses are
expressed as percent change from the contracted levels.
Statistical evaluation of data was performed by the Student t
test for either paired or unpaired observations and by analy-
sis of variance.
Results
Hyaluronidase (3.0 to 15 USP units) produced con-
centration-dependent relaxation in canine coronary
artery segments with endothelium, but no change
occurred in tension of arterial segments without
endothelium (Figs 1, 2, and 3). Endothelium-dependent
relaxation to hyaluronidase was blocked by pretreat-
ment of arterial segments with L-NMMA (10–5 mol/L)
or L-NOARG (10–5 mol/L), 2 competitive inhibitors of
nitric oxide synthesis from L-arginine15,16 (n = 6, each
group; P < .05) (Figs 1, 2, and 3). The inhibitory effect
of L-NMMA could be reversed by the addition of 
L-arginine (10–4 mol/L) but not D-arginine (10–4 mol/L)
(n = 6, each group; P < .05) (Figs 1, 2, and 3).
Endothelium-dependent relaxation to hyaluronidase
also was blocked by pretreating vascular segments with
methylene blue (10–6 mol/L), an inactivator of soluble
guanylate cyclase17,18 (n = 6, P < .05) (Fig 3). The addi-
tion of hemoglobin (10–6 mol/L), a scavenger of the
nitric oxide radical,18 also abolished endothelium-
dependent relaxation to hyaluronidase (n = 6, P < .05)
(Fig 3). Inactivation of the enzymatic activity of
hyaluronidase by heat did not alter endothelium-depen-
dent relaxation to the compound (data not shown).
Discussion
The present study demonstrates that hyaluronidase
induces the release of the endogenous vasodilator nitric
oxide from the arterial endothelium. In the endothelial
cell, nitric oxide is synthesized from the basic amino
acid L-arginine,19 and nitric oxide synthesis can be
blocked by modified forms of the amino acid.15,16
Indeed, in this experiment, endothelium-dependent
vasodilation to hyaluronidase is blocked by L-NMMA
and L-NOARG. The specificity of the competitive inhi-
bition of L-NMMA for L-arginine metabolism was
highlighted by the fact that the action of L-NMMA is
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Fig 2.  Concentration-response curves to hyaluronidase in canine coronary arteries. Segments with and without
endothelium were contracted with prostaglandin F2α (PGF2 alpha; 2 × 10–6 mol/L) and exposed to increasing con-
centrations of hyaluronidase. Values are expressed as mean ± standard error of mean; n = 6, each group. D-Arg, D-
Arginine; L-Arg, L-arginine; L-NMMA, NG-monomethyl-L-arginine. 
reversed by adding exogenous L-arginine but not D-
arginine. In addition, endothelium-dependent vasodila-
tion to hyaluronidase is blocked by hemoglobin, which
is a scavenger of the nitric oxide radical.18 Nitric oxide
activates soluble guanylate cyclase in the vascular
smooth muscle to effect vasodilation.17,18 Methylene
blue is an inhibitor of soluble guanylate cyclase in the
vascular smooth muscle.17,18 When methylene blue is
added to the organ chamber, endothelium-dependent
vasodilation to hyaluronidase is abolished. Endo-
thelium-dependent vasodilation to hyaluronidase does
not involve epoprostenol (Prostacyclin) or other
prostanoids, because vasodilation occurs even after
inhibition of cyclooxygenase by indomethacin. 
Enzymatic activity of hyaluronidase is not required to
produce vasodilation, because inactivation of the
enzyme compound by heat has no effect on vasodila-
tion. This finding raises the possibility of a
hyaluronidase receptor on the endothelial cell surface
that mediates nitric oxide release. Another potential
mechanism is interference with degradation of nitric
oxide by the protein.
In 1959, Martins de Oliveira, Carballo, and
Zimmerman2 reported that in patients with myocardial
infarctions hyaluronidase administration reduces ST-
segment elevation. Subsequently, Maroko and asso-
ciates1 demonstrated that hyaluronidase infusion
diminishes myocardial necrosis in a canine model of
acute coronary artery occlusion. Recently, investigators
examining myocardial preservation found that even
small concentrations of hyaluronidase added to preser-
vation solutions improve functional and metabolic
recovery in donor hearts treated with the compound.5
Although some investigators attribute the protective
action of hyaluronidase to its ability to decrease
myocardial edema and augment cardiac lymphatic
drainage,3,4 the present study indicates that an addi-
tional mechanism could be hyaluronidase-stimulated
release of nitric oxide.
Nitric oxide is an endogenous vascular protectant
released by the intima. Nitric oxide prevents vasospasm
and thrombosis in the coronary artery by inducing
vasodilation, preventing platelet adhesion6 and aggre-
gation,7 and promoting platelet disaggregation20 in the
vasculature. Nitric oxide also protects against cell-
mediated reperfusion injury by preventing leukocyte
adhesion to the intima8 and inhibiting leukocyte aggre-
gation.9 In addition, nitric oxide inactivates superoxide
radicals produced by leukocytes.10,11 Nitric oxide, hav-
ing an unpaired electron, can accept electrons and
thereby inactivate or scavenge O·2–. Thus, nitric oxide
also acts as an endogenous defense against oxygen-
derived free radicals.
By stimulating the endogenous release of nitric
oxide, hyaluronidase activates a powerful system to
protect the vasculature and the myocardium from the
deleterious primary and secondary effects of
ischemia and reperfusion. The present experiments
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Fig 3.  Maximal vasodilation to hyaluronidase in canine coronary artery segments with or without endotheli-
um. Segments with and without endothelium were contracted with prostaglandin F2α (PGF2 alpha; 2 × 10–6
mol/L) and exposed to hyaluronidase (15 units) only (control) or in the presence of NG-monomethyl-L-arginine
(L-NMMA), L-arginine (L-Arg), D-arginine (D-Arg), NG-nitro-L-arginine (NO-Arg), oxyhemoglobin (Hb), or
methylene blue (n = 6, each group). Asterisk denotes significance from arterial segments with endothelium 
(P < .05). 
lend support to the use of hyaluronidase as a vascular
protectant during coronary reperfusion or for
myocardial preservation. 
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